TRIB

MKT CAP:$7M

Trinity Biotech plc

Market Cap

$7M

Healthcare·Medical - Diagnostics & Research·🇮🇪 Ireland·NASDAQ

Healthcare·Medical·🇮🇪·NASDAQ

Stock Price

$0.70-$0.05 (-6.19%)

Apr 22, 2026

Company Details

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offer...

CEO

John Gillard

IPO Date

Oct 21, 1992

Website

www.trinitybiotech.com

Key Metrics TTM

Revenue

$49M

-17.7% YoY

Net Income

-$37M

EPS (Diluted)

-$2.27

Free Cash Flow

-$4M

Revenue / Share

$2.61

Gross Margin

34.7%

Operating Margin

-40.7%

Net Margin

-75.9%

FCF Margin

-8.6%

P/S

0.1x

P/E

—

Earnings Reports

Q3 2025

Oct 23, 2025

$14M-6.0%EPS -$0.27

Q2 2025

Dec 23, 2025

$11M-30.8%EPS -$0.32

Q1 2025

May 15, 2025

$8M-48.5%EPS -$0.48

FY 2024

Dec 31, 2024

$62M+8.3%EPS -$1.77

Q4 2024

Feb 28, 2025

$16M+18.1%EPS -$1.20

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 21	$26M	$11M	$3M
Q3 22	$20M	$2M	-$5M
Q4 22	$18M	$6M	-$5M
Q2 23	$14M	$5M	-$15M
Q3 23	$15M	$4M	-$5M
Q4 23	$13M	$4M	-$3M
Q1 24	$15M	$5M	-$3M
Q2 24	$16M	$6M	-$4M
Q3 24	$15M	$5M	-$3M
Q4 24	$16M	$5M	-$12M
Q1 25	$8M	$2M	-$5M
Q2 25	$11M	$4M	-$3M
Q3 25	$14M	$6M	-$536.6K

Valuation

Quarter	P/S	P/E
Q1 21	—	—
Q3 22	—	—
Q4 22	—	—
Q2 23	2.4x	—
Q3 23	2.0x	—
Q4 23	1.7x	—
Q1 24	1.6x	—
Q2 24	1.9x	—
Q3 24	1.0x	—
Q4 24	1.0x	—
Q1 25	0.7x	—
Q2 25	0.9x	—
Q3 25	0.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 21	$2M	-$594.0K
Q3 22	$676.0K	-$648.0K
Q4 22	$2M	$1M
Q2 23	-$4M	-$5M
Q3 23	-$5M	-$5M
Q4 23	-$966.0K	-$2M
Q1 24	-$5M	-$6M
Q2 24	-$1M	-$4M
Q3 24	-$4M	-$6M
Q4 24	$3M	$615.0K
Q1 25	-$3M	-$3M
Q2 25	-$2M	-$2M
Q3 25	-$71.4K	-$77.1K

Capital Expenditures

Quarter	CapEx
Q1 21	$2M
Q3 22	$1M
Q4 22	$1M
Q2 23	$564.0K
Q3 23	$620.0K
Q4 23	$891.0K
Q1 24	$1M
Q2 24	$3M
Q3 24	$3M
Q4 24	$3M
Q1 25	$56.0K
Q2 25	$37.7K
Q3 25	$5.7K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 23	-42.7%	-14.8%
Q4 23	-31.1%	-30.4%
Q1 24	-18.5%	-22.2%
Q2 24	+14.0%	-30.8%
Q3 24	+3.2%	-7.6%
Q4 24	+18.1%	+61.8%
Q1 25	-48.5%	-30.6%
Q2 25	-30.8%	-29.6%
Q3 25	-6.0%	-16.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 21	$380.0K	1.5%
Q3 22	$119.0K	0.6%
Q4 22	$1M	7.3%
Q2 23	$975.0K	7.0%
Q3 23	$738.0K	5.0%
Q4 23	-$1M	-7.5%
Q1 24	$812.0K	5.5%
Q2 24	$114.0K	0.7%
Q3 24	$250.0K	1.6%
Q4 24	$140.0K	0.9%
Q1 25	$0	0.0%
Q2 25	$0	0.0%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 21	$1M	$6M	—
Q3 22	$1M	—	$6M
Q4 22	$1M	—	$10M
Q2 23	$1M	—	$8M
Q3 23	$1M	—	$8M
Q4 23	$1M	—	$6M
Q1 24	$1M	—	$7M
Q2 24	$991.0K	—	$6M
Q3 24	$1M	—	$7M
Q4 24	$1M	—	$8M
Q1 25	$1M	—	$5M
Q2 25	$646.0K	—	$7M
Q3 25	$813.4K	—	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$26M	$0	$26M
Q1 22	$10M	$0	$10M
Q2 22	$10M	$0	$10M
Q3 22	$7M	$0	$7M
Q4 22	$7M	$0	$7M
Q1 23	$0	$17M	$17M
Q2 23	$0	$27M	$27M
Q3 23	$0	$19M	$19M
Q4 23	$4M	$0	$4M
Q1 24	$6M	$0	$6M
Q2 24	$5M	$0	$5M
Q3 24	$3M	$0	$3M
Q4 24	$5M	$0	$5M
Q1 25	$4M	$0	$4M
Q2 25	$2M	$0	$2M
Q3 25	$1M	$0	$1M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 21	5M	—	—
Q3 22	8M	+68.2%	—
Q4 22	8M	0.0%	—
Q2 23	8M	+0.5%	—
Q3 23	8M	+0.1%	+69.2%
Q4 23	8M	0.0%	+0.6%
Q1 24	9M	+15.7%	+16.4%
Q2 24	9M	+6.7%	+23.6%
Q3 24	10M	+9.7%	+35.5%
Q4 24	14M	+36.5%	+84.9%
Q1 25	18M	+29.1%	+106.3%
Q2 25	19M	+1.8%	+96.8%
Q3 25	19M	+0.1%	+79.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 21	$47.1K	543
Q3 22	$40.9K	477
Q4 22	$45.3K	398
Q2 23	$34.9K	398
Q3 23	$36.9K	398
Q4 23	$35.3K	380
Q1 24	$38.7K	380
Q2 24	$41.7K	380
Q3 24	$39.9K	380
Q4 24	$41.7K	380
Q1 25	$19.9K	380
Q2 25	$28.9K	380
Q3 25	$37.5K	380

Revenue / Employee